uniQure N.V.QURE
...Loading QURE Peers...
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
480 Employees
CEO : Mr. Matthew Craig Kapusta CPA
Address : Paasheuvelweg 25a, Amsterdam, NL, - 1105 BP,
| Key Excutives | Designation |
|---|---|
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Ms. Erin Boyer | Chief People & Culture Officer |
| Mr. Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site |
| Eileen Sawyer | Vice President of Global Medical Affairs |
| Mr. Matthew Craig Kapusta CPA | Chief Executive Officer & Executive Director |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary |